Top-line results from the PALISADE-4 phase III trial showed no significant benefit for fasedienol in the overall population, but post-hoc analyses revealed significant efficacy in patients with very severe social anxiety disorder. Plans are underway to shift the registrational pathway to use LSAS as the primary endpoint, supported by favorable safety data and prior positive trials.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.